Cboe CA - Delayed Quote CAD

Eli Lilly and Company (LLY.NE)

29.78

+0.40

+(1.36%)

At close: January 10 at 3:58:40 PM EST

FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?

The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Manufactured by Eli Lilly and Company, Zepbound offers a new approach to managing OSA symptoms while also promoting significant weight loss. What Is Zepbound? Zepbound is an injectable prescription medication created to help adults with obesity and weight-related problems, including obstruc

Benzinga 8 hours ago

LLY
Sector Update: Health Care Stocks Weaker Late Afternoon

Health care stocks were decreasing late Friday afternoon, with the NYSE Health Care Index down 0.6%

PREMIUM
MT Newswires yesterday

LLY
AI, vaccine distrust, & the future of healthcare: Novartis CEO

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart its stock price.  In the last year, Novartis shares have declined 6.69%. During that same timespan, the S&P 500 and Dow Jones Industrial Average have gained 22.8% and 12%, respectively. The iShares U.S. Healthcare ETF (IYH) is up slightly in the past year. The stock prices of Pfizer (PFE) and Moderna (MRNA) are down 8.5% and 61%, respectively in the past year. For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website.

Yahoo Finance Video yesterday

PFE

NVS

NVSEF
Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity

(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.Most Read from BloombergWhat Robotaxis Brought San FranciscoNYC Condo Owners May Bear Costs of Landmark Green Building LawAmbitious High-Speed Rail Plans Advance in the Baltic RegionA Blueprint for Better Bike LanesNYC’s Subway Violence Deters Drive to Bring Workers Back to OfficeCompanies including Biogen Inc. and Eli Lilly & Co. h

Bloomberg yesterday

BIIB

LLY

ROG.SW
Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point.

The president-elect might bring back efforts to make other countries pay more for drugs, but there are pitfalls.

The Wall Street Journal yesterday

LLY
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Zacks 2 days ago

NVO

LLY
Is Eli Lilly and Company (LLY) the Best Blue Chip Stock to Buy for 2025?

We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best blue chip stocks to buy for 2025. Both conservative and risk-tolerant investors favor blue chip stocks due to their […]

Insider Monkey 2 days ago

LLY

^GSPC
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month.

Investopedia 2 days ago

LLY

NVO
Medicare Will Pay for Zepbound for Some Patients. The Costs Could Be Huge.

The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that afflicts many severely obese people.

Barrons.com 2 days ago

LLY
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy

Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.

Zacks 2 days ago

NVO

LLY
LLY Falls Around 14% in 3 Months: How to Play the Stock

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.

Zacks 2 days ago

LLY

NVO
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investor's Business Daily 2 days ago

AMGN

LLY

PFE
5 questions facing pharma in 2025

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

BioPharma Dive 2 days ago

LLY

NVO
The most and least expensive weight loss drugs, ranked

Sales of blockbuster weight-loss drugs have surged in 2024 and are projected to continue rising in the coming years. The medications, which belong to the class of drugs called GLP-1s and were popularized by the diabetes treatment Ozempic, help regulate blood sugar levels and suppress appetite.

Quartz 2 days ago

LLY
3 Stocks to Buy for 2025 That Are Practically Money Machines

You won't find many companies that rake in greater sales than Amazon (NASDAQ: AMZN). The e-commerce and cloud services giant generated revenue of roughly $620 billion over the last 12 months. The consensus revenue estimate for Amazon in 2025 among analysts surveyed by LSEG is around $707 billion.

Motley Fool 2 days ago

AMZN

GOOG

LLY
Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey

Companies have slowly been increasing coverage of GLP-1s for weight loss. Still, fewer than 50% do so.

Yahoo Finance 3 days ago

LLY

NONOF

NVO
Novo Nordisk Received an Upgrade from UBS for Its Ozempic and Wegovy's Strong Brand Recognition

Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products

GuruFocus.com 3 days ago

NVO

LLY
Trump suggests Denmark tariff. How it could hit Novo Nordisk.

President-elect Donald Trump threatened higher tariffs against longtime ally Denmark over its ownership of Greenland as a Danish territory; Trump even floated the idea of the US purchasing Greenland. Denmark-based pharmaceutical company Novo Nordisk (NVO) is a major company that could be heavily impacted if Trump were to impose such tariffs. Yahoo Finance senior health reporter Anjalee Khemlani explains Novo Nordisk's presence in the US, especially as a GLP-1 weight-loss drug manufacturer, and what US companies like Eli Lilly (LLY) could have to gain if tariffs were levied against Denmark producers. Trump has proposed new tariff policy proposals that he could enact using the International Economic Emergency Powers Act (IEEPA). To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 3 days ago

LLY

NONOF

NVO
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due to their successful diabetes and weight loss medications. One study suggests that it may even help reduce the risk of developing Alzheimer's. There are many illnesses and conditions which are associated with being obese, which is why it's paramount for many patients to maintain a healthy weight.

Motley Fool 3 days ago

NVO

LLY
5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of America addresses the company’s earnings and more.

Barrons.com 3 days ago

NVO

LLY

Performance Overview

Return	LLY.NE	S&P 500
YTD	+3.33%	-1.35%
1-Year	+27.06%	+22.51%
3-Year	+36.48%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eli Lilly and Company (LLY.NE)

FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?

Sector Update: Health Care Stocks Weaker Late Afternoon

AI, vaccine distrust, & the future of healthcare: Novartis CEO

Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity

Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point.

Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?

Is Eli Lilly and Company (LLY) the Best Blue Chip Stock to Buy for 2025?

Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea

Medicare Will Pay for Zepbound for Some Patients. The Costs Could Be Huge.

NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy

LLY Falls Around 14% in 3 Months: How to Play the Stock

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

5 questions facing pharma in 2025

The most and least expensive weight loss drugs, ranked

3 Stocks to Buy for 2025 That Are Practically Money Machines

Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey

Novo Nordisk Received an Upgrade from UBS for Its Ozempic and Wegovy's Strong Brand Recognition

Trump suggests Denmark tariff. How it could hit Novo Nordisk.

This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly

5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher

Performance Overview